CA3197311A1 - Compositions d'oligonucleotides et procedes associes - Google Patents

Compositions d'oligonucleotides et procedes associes

Info

Publication number
CA3197311A1
CA3197311A1 CA3197311A CA3197311A CA3197311A1 CA 3197311 A1 CA3197311 A1 CA 3197311A1 CA 3197311 A CA3197311 A CA 3197311A CA 3197311 A CA3197311 A CA 3197311A CA 3197311 A1 CA3197311 A1 CA 3197311A1
Authority
CA
Canada
Prior art keywords
methods
oligonucleotide compositions
compositions
present disclosure
disclosure provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3197311A
Other languages
English (en)
Inventor
Prashant MONIAN
Chikdu Shakti SHIVALILA
Subramanian Marappan
Chandra Vargeese
Pachamuthu Kandasamy
Genliang Lu
Hui Yu
David Charles Donnell Butler
Luciano Henrique APPONI
Mamoru Shimizu
Stephany Michelle STANDLEY
David John BOULAY
Andrew Guzior HOSS
Jigar Desai
Jack David GODFREY
Hailin Yang
Naoki Iwamoto
Jayakanthan Kumarasamy
Anthony LAMATTINA
Tom Liantang PU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wave Life Sciences Pte Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3197311A1 publication Critical patent/CA3197311A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne entre autres des oligonucléotides et des compositions associées. Dans certains modes de réalisation, l'invention concerne des oligonucléotides et des compositions utiles pour la modification de l'adénosine. Dans certains modes de réalisation, la présente invention concerne des méthodes de traitement de divers états, troubles ou maladies qui peuvent tirer avantage d'une modification de l'adénosine.
CA3197311A 2020-11-08 2021-11-08 Compositions d'oligonucleotides et procedes associes Pending CA3197311A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063111079P 2020-11-08 2020-11-08
US202163175036P 2021-04-14 2021-04-14
US202163188415P 2021-05-13 2021-05-13
US202163196178P 2021-06-02 2021-06-02
US202163248520P 2021-09-26 2021-09-26
PCT/US2021/058495 WO2022099159A1 (fr) 2020-11-08 2021-11-08 Compositions d'oligonucléotides et procédés associés

Publications (1)

Publication Number Publication Date
CA3197311A1 true CA3197311A1 (fr) 2022-05-12

Family

ID=81456778

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3197311A Pending CA3197311A1 (fr) 2020-11-08 2021-11-08 Compositions d'oligonucleotides et procedes associes

Country Status (8)

Country Link
EP (1) EP4240849A1 (fr)
JP (1) JP2023548584A (fr)
KR (1) KR20230118716A (fr)
AU (1) AU2021373062A1 (fr)
CA (1) CA3197311A1 (fr)
IL (1) IL302558A (fr)
MX (1) MX2023005326A (fr)
WO (1) WO2022099159A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7296882B2 (ja) 2016-11-23 2023-06-23 ウェイブ ライフ サイエンシズ リミテッド ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法
JP2020524485A (ja) 2017-06-02 2020-08-20 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． オリゴヌクレオチド組成物及びその使用方法
CN111051281A (zh) 2017-06-21 2020-04-21 波涛生命科学有限公司 用于合成的化合物、组合物和方法
WO2019032612A1 (fr) 2017-08-08 2019-02-14 Wave Life Sciences Ltd. Compositions oligonucléotidiques et méthodes associées
JP7472018B2 (ja) 2017-09-18 2024-04-22 ウェーブ ライフ サイエンシーズ リミテッド オリゴヌクレオチド調製のための技術
WO2023278410A1 (fr) * 2021-06-29 2023-01-05 Korro Bio, Inc. Procédés et compositions pour édition médiée par adar
CA3232965A1 (fr) * 2021-09-26 2023-03-30 Christopher Michael ACKER Compositions pour l'edition de transcrits mecp2 et procedes associes
CA3234835A1 (fr) * 2021-10-22 2023-04-27 Korro Bio, Inc. Procedes et compositions pour perturber l'interaction de la proteine nrf2-keap1 par l'edition d'arn a mediation adar
WO2023152371A1 (fr) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Oligonucléotides guides pour l'édition d'acides nucléiques dans le traitement de l'hypercholestérolémie
WO2024013361A1 (fr) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucléotides pour édition d'arn médiée par adar et leur utilisation
WO2024013360A1 (fr) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucléotides chimiquement modifiés pour édition d'arn médiée par adar
WO2024017817A1 (fr) * 2022-07-18 2024-01-25 F. Hoffmann-La Roche Ag Oligonucléotide d'édition
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
CN116444593B (zh) * 2023-04-28 2023-12-26 南通大学 一种7-脱氮鸟苷亚磷酰胺单体的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074597A1 (fr) * 2012-11-06 2014-05-15 President And Fellows Of Harvard College Compositions et procédés se rapportant à des nanostructures d'acides nucléiques complexes
EP3507366B1 (fr) * 2016-09-01 2020-10-07 ProQR Therapeutics II B.V. Oligonucléotides d'édition d'arn simple brin chimiquement modifiés
KR20200026804A (ko) * 2017-05-18 2020-03-11 더 브로드 인스티튜트, 인코퍼레이티드 표적화된 핵산 편집을 위한 시스템, 방법 및 조성물
CN111051281A (zh) * 2017-06-21 2020-04-21 波涛生命科学有限公司 用于合成的化合物、组合物和方法

Also Published As

Publication number Publication date
WO2022099159A1 (fr) 2022-05-12
JP2023548584A (ja) 2023-11-17
KR20230118716A (ko) 2023-08-11
EP4240849A1 (fr) 2023-09-13
MX2023005326A (es) 2023-07-31
IL302558A (en) 2023-07-01
AU2021373062A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
CA3197311A1 (fr) Compositions d'oligonucleotides et procedes associes
MX2022004101A (es) Composiciones de oligonucleotidos y metodos de uso de las mismas.
WO2020227691A3 (fr) Compositions oligonucléotidiques et leurs procédés d'utilisation
WO2021071788A3 (fr) Compositions oligonucléotidiques et leurs procédés d'utilisation
WO2020219981A3 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
WO2021178237A3 (fr) Compositions oligonucléotidiques et méthodes associées
EP2450040A3 (fr) Compositions et kits permettant de traiter la grippe
EP2239328A3 (fr) Procédés et compositions pour traiter une maladie neurologique
WO2005004794A3 (fr) Procede de traitement de maladie neurodegenerative
EP2426203A3 (fr) Agents utiles pour le traitement de la dystrophie musculaire facio-scapulo-humérale
EP1676512A3 (fr) Articles pour traitement de la peau et méthodes
WO2001098317A3 (fr) Alpha-glycosylceramides destines au traitement d'infections bacteriennes et fongiques
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2022031847A3 (fr) Compositions et méthodes d'inhibition de l'expression de plp1
EP2862867A3 (fr) Procédés et compositions pour le traitement du syndrome de Marfan et troubles associés
WO2016168762A3 (fr) Anticorps anti-pacap et leurs utilisations
EP1463531A4 (fr) Procede pour inhiber des processus oculaires
WO2021178749A3 (fr) Agents anti-ccr8
WO2004080418A3 (fr) Composes d'acide nucleique pouvant inhiber l'angiogenese et la croissance tumorale
WO2007035814A8 (fr) Reactifs, methodes et trousses destines a la classification de champignons et a l'application d'un traitement antifongique
WO2005099702A3 (fr) Derives de r(?)-11-hydroxyaporphines et utilisations de ces derives
WO2019175260A3 (fr) Oligonucléotides modifiés et méthodes d'utilisation dans les tauopathies
WO2021081292A8 (fr) PROCÉDÉS DE TRAITEMENT DE TROUBLES NEUROLOGIQUES AVEC DES AGONISTES α1A-AR PARTIELS
WO2021032777A8 (fr) Compositions de conjugués d'oligonucléotides et méthodes d'utilisation
WO2007064853A3 (fr) Oligonucleotides d'acide nucleique bloque